688176 亚虹医药
2024/06 - 中期2023/122022/122021/122020/12

盈利能力分析
净资产收益率 ROE (%)-8.051-15.524-8.525-12.303-59.210
总资产报酬率 ROA (%)-7.249-14.545-8.256-11.919-53.964
投入资产回报率 ROIC (%)-7.550-15.076-8.472-12.247-30.787

边际利润分析
销售毛利率 (%)78.55278.99873.02284.989--
营业利润率 (%)-229.125-2,937.490-948,649.406-5,210,058.993--
息税前利润/营业总收入 (%)-247.781-3,197.334-1,037,721.275-5,122,199.049--
净利润/营业总收入 (%)-228.995-2,914.455-944,804.606-5,135,637.810--

收益指标分析
经营活动净收益/利润总额(%)105.536107.943125.221108.671102.072
价值变动净收益/利润总额(%)-7.094-6.324-23.476-6.975-1.484
营业外收支净额/利润总额(%)0.147-0.623-0.932-1.5330.111

偿债能力分析
流动比率 (X)10.12912.81634.21740.71621.973
速动比率 (X)10.11912.80834.18240.66521.860
资产负债率 (%)10.6339.2133.5832.7744.407
带息债务/全部投入资本 (%)4.9093.065-0.1300.176--
股东权益/带息债务 (%)1,890.6603,089.060-76,383.98556,417.4933,393,755.384
股东权益/负债合计 (%)839.911984.7232,690.8053,504.3562,169.060
利息保障倍数 (X)13.52611.50010.607-558.185-146.557

营运能力分析
应收账款周转天数 (天)45.192113.751141.021342.000--
存货周转天数 (天)18.265274.394168,675.3492,100,090.830--